Achaogen to Present New Data on ACHN-490 at the 50th Annual ICAAC Meeting

- Presentations Highlight Data from Phase 1 Study with ACHN-490 and In Vitro Activity of ACHN-490 Against Resistant Bacterial Pathogens and in Combination with Existing Antibiotics -

SOUTH SAN FRANCISCO, Calif., September 9, 2010 – Achaogen, a biopharmaceutical company and developing antibiotics to treat life-threatening, multi-drug resistant (MDR), today announced key upcoming data presentations involving its lead antibiotic candidate ACHN-490. The data are being presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston from September 12th through September 15th, 2010.

  •  Monday, September 13th from 11:15 am to 1:15 pm: Poster A1-658/7, entitled “Pharmacokinetics (PK) and Safety of ACHN-490 Injection Administered Intravenously for Five Days in Healthy Human Subjects.”
  •  Tuesday, September 14th from 11:15 am to 1:15 pm: Poster E-1563/226, entitled “Activity of ACHN-490 Against Isolates of Methicillin-resistant Staphylococcus aureus (MRSA) from Patients in U.S. Hospitals.”
  •  Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2059/74, entitled “Activity of ACHN-490, a Neoglycoside, against E. coli (EC) and K. pneumoniae (KP) isolates from New York City (NYC).”
  •  Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2048/63, entitled “Activity of ACHN- 490 +/- Cefepime, Doripenem, Imipenem, or Piperacillin/Tazoactam Against 10 P. aeruginosa by Synergy Time-Kill.”

In addition to the poster presentations, on Monday, September 15th from 9:00 am to 9:30 am, George H. Miller, Ph.D., research fellow at Achaogen, will be presenting “Aminoglycosides: Past, Present and Future” as part of the Symposium: “Antibiotic Drug Discovery: How Far Have We Come in 50 Years?” Following the meeting, full versions of the posters will be available on the Achaogen website at www.achaogen.com.

About ACHN-490
Achaogen’s most advanced compound, ACHN-490, has been chemically engineered to retain activity against bacteria resistant to carbapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides. The compound has demonstrated bactericidal activity in vitro and efficacy in preclinical studies against systemic infections caused by MDR Gram-negative bacteria (e.g., K. pneumoniae, E. coli, and P. aeruginosa) and MRSA. ACHN-490 Injection is currently being investigated in a randomized, doubleblind, comparator-controlled Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI), the most commonly treated hospital infections in the U.S., and acute pyelonephritis.

About Achaogen
Achaogen is a biopharmaceutical company focused on the discovery and development of antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs, and has funded its growth with an innovative blend of private investments and non-dilutive funding from partnerships with the NIH, BARDA, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com. 

Contacts:
Ashlea Kosikowski, Pure Communications
(910) 547-7093